Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon alpha2b in patients with suboptimal molecular response or stable detectable molecular residual disease after at least two years of imatinib treatment (NordDutchCML009)

X
Trial Profile

A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon alpha2b in patients with suboptimal molecular response or stable detectable molecular residual disease after at least two years of imatinib treatment (NordDutchCML009)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary) ; Peginterferon alfa-2b (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Acronyms NordDutchCML009
  • Most Recent Events

    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Status changed from recruiting to discontinued as the recruitment of patients was difficult, according the results presented at the 22nd Congress of the European Haematology Association
    • 02 Feb 2017 This trial was discontinued in Netherlands, according to European Clinical Trials Database.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top